P
ITUITARY ADENOMAS ARE benign neoplasms of adenohypophysial cells. They represent the most common neoplasm of the sellar region, amounting approximately 15% of all primary intracranial tumors. In studies of unselected adult autopsy material, their frequency as an incidental finding varies between 5 and 20% in different studies. Pituitary adenomas cause considerable morbidity due to local invasion, hypopituitarism, or hormone hypersecretion (1, 2) . Evidence indicates that pituitary adenomas are of monoclonal origin (3) . This pathogenesis should give rise to five well-defined tumor types, derived from each one of the normal anterior pituitary (AP) cell types. Contrary to this expectation, pituitary adenomas are extremely heterogeneous and have been difficult to type (4) . They are classified according to morphometric and secretory characteristics (1, 4) as prolactinomas [excess prolactin (PRL) secretion], GHomas or somatotrophinomas (excess GH secretion leading to gigantism or acromegalia), ACTHomas (resulting in pituitary Cushing's disease), nonfunctioning adenomas (those not leading to excess hormone secretion or endocrine changes), and the least frequent adenomas secreting either TSH or gonadotropins. Finally, although less common, some pituitary tumors produce more than one pituitary hormone.
A comprehensive characterization of pituitary tumors according to their cell phenotypes is lacking.
Pituitary tumors are also frequently characterized by the so-called paradoxical secretion (5, 6) , which is secretion of a given AP hormone induced by a noncorresponding hypothalamic-releasing hormone (HRH). For instance, paradoxical secretion of GH induced by TRH and/or LHRH has been variably reported in pituitary tumors (5, 7) . Multihormonal responses to CRH have been reported in Cushing's disease (8) . GHRH has been reported to induce PRL secretion both in acromegalic (9) and Cushing's syndrome patients (10) . The underlying mechanisms are not known. Paradoxical secretion has also been sporadically reported in the normal pituitaries, both in vivo and in vitro, including in healthy humans (10 -12) .
It has been shown recently that normal mouse and rat AP contain cells expressing multiple HRH receptors (13) (14) (15) (16) , which could be responsible for paradoxical secretion of PRL (15) . A growing body of evidence suggests that, contrary to the orthodox view, 20 -40% of the rat and the mouse AP cells are multifunctional and exhibit mixed phenotypes, storing multiple AP hormones (polyhormonal) and/or expressing multiple HRH receptors (multiresponsive) and/or multiple AP hormone mRNAs (15) (16) (17) . It has been suggested that multifunctional AP cells may be involved in cell plasticity processes directed to increase hormone production during demanding physiologic or pathophysiologic situations such as lactation, ovulation, hypothyroidism, etc. (18 -20) . Whether human pituitary adenomas do contain cells with mixed phenotypes is not known, but if they do, that could help to explain paradoxical secretion and/or tumorigenesis.
Here we have characterized the cell phenotypes present in human pituitary adenomas according to the AP hormones stored and the HRH receptors expressed. This was achieved by a novel approach that combines calcium imaging of freshly dispersed cells and multiple sequential primary immunocytochemistry (MSPI) of the six AP hormones in the same cells (16) . Using this methodology, we have typed individual cells from 15 pituitary tumors including five prolactinomas, three pituitary adenomas from multiple endocrine neoplasia type I (MEN-I) patients, four nonfunctioning adenomas, and three adenomas from pituitary Cushing's disease patients. The phenotypic characteristics were very heterogeneous not only among different types of tumors but also among different tumors of the same class. Many tumor cells expressed multiple receptors for different HRHs providing the basis for paradoxical secretion in human pituitary adenomas.
Materials and Methods Materials
Antisera against human AP hormones FSH␤ (AFP891891), GH (AFPC11981A), LH␤ (AFP55951889), PRL (AFP55781789), TSH␤ (AFP55741789), and ACTH (AFP39032082Rb) were generous gifts from the National Hormone and Pituitary Program (Torrance, CA) and Dr. A. F. Parlow. The human HRHs (GHRH, TRH, LHRH, and CRH) were purchased from Sigma (Madrid, Spain). Fluorescent antibodies were prepared by labeling with Oregon Green 488, Cascade Yellow, or Alexa 350 and purified over a protein A-Sepharose column (16) . Fura-2/AM, Oregon Green 488-isothiocyanate, Cascade Yellow succinimidyl ester, and Alexa 350 succinimidyl ester were purchased from Molecular Probes (Eugene, OR).
Pituitary tumor cell culture
All the procedures used here were approved by the university hospitals and School of Medicine ethical committees. Selected patients were asked to read carefully and, if pertinent, to sign the informed consent form approved by the university hospital ethical committee. Fresh pituitary tumoral tissue was obtained from patients from the two Valladolid University hospitals (Valladolid, Spain) at the time of surgery. Extreme care was taken to ensure that samples for analysis were devoid of any contaminating normal tissue. The adenoma nature as well as the lack of contamination of the samples was confirmed later by pathological analysis of the samples. Although it is possible that a few normal cells contaminated our adenoma cultures, we believe that their contribution to the results shown here is not significant. The tissue was transferred to MEM (Invitrogen, Carlsbad, CA) at 4 C and quickly dispersed with trypsin (1 mg/ml) for 15-30 min at 37 C. Dispersed cells were plated on coverslips previously coated with 0.01 mg/ml poly-l-lysine and cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum and antibiotics until use.
Calcium imaging
Calcium imaging was carried out as previously reported (15, 16) . Briefly, cells were incubated with fura-2/AM (4 m) for about 1 h at room temperature in standard medium: 145 mm NaCl, 5 mm KCl, 1 mm MgCl 2 , 1 mm CaCl 2 , 10 mm HEPES, (pH 7.4), and 10 mm glucose. Then, cells were washed in the same medium, placed in a thermostatically controlled (37 C) stage of an inverted microscope (Diaphot; Nikon, Tokyo, Japan), and perifused with standard medium, prewarmed at 37 C. Cells were epi-illuminated alternately at 340 and 380 nm, and light emitted above 520 nm was recorded by using a Magical Image Processor (Applied Imaging, Newcastle, UK). Pixel-by-pixel ratios of consecutive frames were produced, and cytosolic calcium concentration ([Ca 2ϩ ] i ) was estimated from these ratios by comparison with fura-2 standards. Figure 1Aa shows an image during stimulation with TRH. Test solutions containing HRHs at 10 nm were perifused for 30 sec at the times indicated. A depolarizing solution containing high K ϩ (75 mm) was perifused for 15 sec at the end of the experiment. Cells not responding to the high K ϩ stimulus (usually Ͻ5% of the total) were excluded from analysis.
MSPI
At the end of the calcium imaging experiment, cells kept in the microscope stage were fixed with 4% paraformaldehyde in PBS, permeabilized with 0.3% Triton X-100, and washed with PBS. Then, 10% goat serum in PBS was added. After 5 min, cells were incubated with antibodies against three human AP hormones (TSH, FSH, and LH) labeled with Oregon Green 488, Cascade Yellow, and Alexa 350, respectively. After washing, specific fluorescence images corresponding to each fluorophore were captured to reveal stained cells with the following fluorescence settings: Oregon Green (FSH): excitation, 490 nm; emission, greater than 510 nm; Cascade Yellow (TSH): excitation, 380 nm, emission, greater than 510 nm; and Alexa 350 (LH): excitation, 340 nm; emission, greater than 450 nm. This step enables typing cells storing TSH, LH, or FSH as well as cells costoring combinations of these AP hormones. Once the first series of images were captured and stored, cells were washed and incubated again with antibodies against GH, PRL, and ACTH labeled with Oregon Green 488 (PRL), Cascade Yellow (GH), and Alexa 350 (ACTH), respectively, and the incubation was continued for 30 min. Then, cells were washed, and three new fluorescence images were taken with the same fluorescence settings described above. This new series of images revealed cells stained by the first antibody plus those newly stained by the second one. Cells stained by the second series of antibodies were revealed by subtracting the first series from the second one. Figure 1Ab shows the merger of the staining with the different antibodies in a representative experiment. Finally, nuclei were stained with Hoechst 33258 (0.5 g/ml, 10 min; Fig. 1Ac ), and another fluorescence image was acquired (excitation, 340 nm; emission, Ͼ420 nm). The nuclear images permitted distinguishing individual cells that were physically close. In all cases, the analysis was performed within 4 h after surgery and on the next day to achieve one to five independent experiments for each tumor cell dispersion. In most cases, an additional multiple sequential immunocytochemistry was carried out on cells neither loaded with fura-2 nor subjected to sequential stimulation with HRHs. Finally, a classic immunocytochemical analysis in tissue sections was carried out by the pathologists. All three procedures yielded similar results.
This procedure has been tested and established previously in normal pituitary cells from mice (16) . Specific controls included the following: 1) perfusion of the cells with hypothalamic releasing factors did not alter responsiveness and 2) multiple sequential immunocytochemistry analysis carried out in cells from the same cultures before and after sequential stimulation with HRHs did not affect either the distribution or the relative abundance of hormone-positive cells (for a more detailed description of this procedure, see Ref. 16 ).
Results
Most relevant clinical and pathological details of the 15 human pituitary adenomas studied here are summarized in Table 1 . Figure 1 summarizes the strategy followed for phenotypic characterization of the cells, which has been established and validated previously with normal mouse pituitary cells (16) . First, cells were loaded with fura-2 and subjected to a protocol of sequential stimulation with the four HRHs and Ca 2ϩ imaging (Fig 1Aa) . The increase of the [Ca 2ϩ ] i in target cells (21-24) reveals expression of functional HRH receptors. The image shown here was taken during stimulation with TRH and shows that six of the eight cells present in the field responded to this releasing hormone. At the end of the imaging experiment, the cells were subjected to MSPI (Fig. 1Ab ) to reveal storage of the different AP hormones. In this case, two cells stored PRL (in green), one GH (in red), and five stored both PRL and GH (in yellow). Finally, the total number of cells was established by staining the nuclei (Fig. 1Ac) , here confirming that there were eight different cells in the field. Figure 1B shows illustrative examples of the cell phenotypes found in different tumors. In prolactinomas, the cells generally stained only for PRL and responded either only to TRH (Fig. 1Ba) or to several HRHs (Fig. 1Bb) . Cells from MEN-1 patients showed no staining or stored PRL and responded only to TRH (Fig. 1Bc) or to both CRH and TRH (Fig. 1Bd) .
Nonfunctioning adenomas usually contained cells that responded to several HRHs and either showed no staining for any AP hormone (Fig. 1Be) or stained with multiple antibodies (Fig. 1Bf) . Finally, cells from Cushing's disease patients may store either ACTH alone or several hormones and respond either solely to CRH (Fig. 1Bg) or to several HRHs (Fig. 1Bh) . These examples document the heterogeneity found among different tumors and also among tumors of the same type. In addition, our data show clearly that cells from human pituitary tumors are multifunctional and may respond to multiple HRHs. 
Phenotypic analysis of prolactinomas
We have used the above described strategy to type cells derived from five prolactinomas (tumors 1-5; Table 1 ). MSPI revealed that all the cells from tumors 1 and 2 stained strongly for PRL. All the cells from tumor 3 stored PRL, but 7% of the cells also contained TSH. In tumor 4, most (Ͼ70%) cells stored PRL, and 14% also stored GH. Finally, in tumor 5, all the cells stained for both PRL and GH. Figure 2 shows the percentage of cells responding to each HRH. The rightmost black bar shows the percentage of multiresponsive cells (cells responding to Ͼ1 HRH). Results for two representative prolactinomas (2 and 5), and the averages of all the five studied are shown. Most cells from tumor 2 responded to TRH, and 25% were multiresponsive. Tumors 3 and 4 were very similar (data not shown). Thus, these three prolactinomas were composed essentially of cells storing only PRL and responding mostly to TRH, a phenotype similar to the normal mammotrope. Tumor 1 was similar in storing only PRL, but cells responded both to TRH (70%) and to CRH (90%). The percentage of multiresponsive cells was 72% (not shown). Finally, prolactinoma 5 was composed entirely by bihormonal cells containing both GH and PRL (mammosomatotropes); they responded not only to TRH and CRH but also to LHRH and specifically to GHRH (Fig. 2) . Up to 85% of the cells of this tumor were multiresponsive. Thus, the cell phenotypes differed greatly among the different prolactinomas. Multiresponsiveness was variable but present in all the five tumors studied here.
Phenotypic analysis of pituitary adenomas from MEN-1 patients
We have also studied three pituitary tumors from patients diagnosed of type I MEN-I (6 -8; Table 1 ). Virtually all the cells from the three tumors stained only for PRL and were negative for the rest of the AP hormones except for about 1% of the cells in tumors 7 and 8 that showed also staining for GH. Figure 3 shows characterization of tumors 7 and 8 as well as the average responses of all the three MEN-1 adenomas. In all the cases, the most prominent responses were to TRH, but responses to the other HRHs were also observed. Specifically, responses to CRH ranged between 25 and 80%, whereas responses to LHRH varied between 9 and 50%. Finally, responses to GHRH were less frequent (15-27%) in tumors 6 and 7 but increased to 80% in tumor 8. Multiresponsive cells varied between 30 and 91%. In conclusion, MEN-I-related AP adenomas were composed of cells storing only PRL but bearing multiple HRH receptors, but otherwise they were very heterogeneous.
Phenotypic analysis of nonfunctioning adenomas
We also studied four nonfunctioning macroadenomas (tumors 9 -12; Table 1 ). Figure 4 shows the phenotypic profiles of three of them. As expected, some tumors (9 and 12) stored no hormones. However, cells from tumor 10 stored ACTH, GH, and/or PRL, and nearly all the cells from tumor 11 stored both PRL and GH. Regarding responsiveness, most of the cells from all the four tumors showed striking responses to all the four HRHs. Specifically, responses to TRH and CRH were very prominent (70 -100% for TRH and 45-71% for CRH). Responses to LHRH and GHRH were very variable (15-70% for LHRH and 5-76% for GHRH). Thus, ironically, the nonfunctioning tumors contained many multiresponsive cells (61-86%) specifically sensitive to TRH and CRH (Fig. 4) . In addition, nonfunctioning pituitary adenoma cells may store one or multiple AP hormones despite excess hormone secretion that was not clinically evident (Table 1) . c All the patients with nonfunctioning pituitary adenoma were diagnosed on the basis of visual defects and magnetic resonance imaging analysis revealing macroadenomas. Their plasma PRL levels were normal (between 14 and 20 ng/ml), and the remaining analytical data were normal as well. d Cushing's disease patients exhibited hypercortisolism with plasma cortisol levels (0800 h) from 24.7-33.1 g/100 ml (normal reference range 5.5-23.1 g/100 ml) and 24-h urine cortisol from 324 -1915 g (normal reference range 24 -135 g/24 h).
Phenotypic analysis of pituitary Cushing's disease adenomas
We studied three AP adenomas obtained from patients suffering pituitary Cushing's disease (Table 1 ). Figure 5 summarizes this analysis. Cells from tumor 13 showed an interesting phenotype. Most of the cells (Ͼ95%) stored ACTH, LH, FSH, and TSH, and a large fraction also contained GH (71%) and/or PRL (43%). Paradoxically, cells from this adenoma were quite responsive to TRH and LHRH but not to CRH. Nearly 50% of the cells were multiresponsive. The second tumor (14) was very different. Most cells stored only ACTH and responded to CRH (82%). Responses to TRH were significant (37%), and cells responding to LHRH (15%) or GHRH (22%) were less abundant. Multiresponsive cells amounted 40% of the cells. The third tumor (15) displayed still a different pattern. We found cells storing PRL (33%) and/or GH (30%) and minor subpopulations containing each of the remaining AP hormones. This cell distribution resem- bles more a normal pituitary than a tumor, except because all cells also showed slight staining for ACTH. Multiresponsiveness approached 50%. Thus, AP tumor cells from pituitary Cushing's disease patients exhibited very different phenotypic patterns. In all the cases, about half of the cells showed responses to multiple HRHs, especially to CRH and TRH.
Multifunctional cells in AP tumors
It seems clear from the above-described data that human pituitary tumor cells may exhibit very different phenotypes, including mixed phenotypes with cells storing more than one AP hormone (polyhormonal cells) and/or bearing multiple HRH receptors (multiresponsive cells). Figure 6 compares the average relative abundance of multiresponsive cells (solid bars) and polyhormonal cells (empty bar) within each type of tumor. Multiresponsive cells varied between 40 and 70%, whereas polyhormonal cells were 2-50%. In eight of 15 tumors, more than 80% of the cells were either multiresponsive and/or polyhormonal. On average, 68% of the cells in all tumors presented a multifunctional phenotype.
Discussion
We present here the first complete phenotypic characterization of individual pituitary tumor cells according to the AP hormones they store and the functional HRH receptors they express. Cell phenotypes varied largely among different tumors and also among tumors of the same type. In addition, most tumors contained large subpopulations of cells with mixed phenotypes, expressing multiple HRH receptors and, much less frequently, storing multiple AP hormones. In eight of 15 tumors, more than 80% of the cells were multifunctional (multiresponsive and/or polyhormonal). A similar study has not been performed in normal human pituitaries, but the fraction of multifunctional cells in mice and rat pituitary was smaller, between 20 and 40% (15, 16) . The increased fraction of multifunctional cells could explain why paradoxical secretion is not infrequent in pituitary tumor patients (5) (6) (7) (8) (9) (10) and much less frequently reported in normal subjects.
It is thought that multifunctional cells are involved in pituitary plasticity. Multifunctional cells seem to be generated by phenotypic switches between mature cell types without cell division, a process called transdifferentiation. This concept was introduced to explain the existence of mammosomatotropes, a cell type that stores and secretes both GH and PRL. Mammosomatotropes are generated by the conversion of somatotropes into mammotropes during situations demanding large amounts of PRL, such as lactation (18) . The concept of transdifferentiation was further extended to include paradoxical expression of HRH receptors. Thus, Childs (19) showed that somatotropes can transiently express GnRH receptors and gonadotropins (LH and FSH) and proposed that this process underlies the surge-dependent GH secretion required for ovulation. In addition, somatotropes may transdifferentiate to thyrosomatotropes during protracted hypothyroidism in humans (20) . The presence of multifunctional cells has been documented within all the five AP cell types in normal mice (16, 17) , suggesting that transdifferentiation can take place in all these cell types under physiological conditions. Thus, pituitary plasticity may be subsidized by phenotypic changes of the individual cells to take care of changing AP hormone demands in different physiological and pathophysiological situations. Now, we find that multifunctional cells are abundant in most of the pituitary adenomas studied, suggesting that pituitary adenomas might arise from transformation and proliferation of multifunctional AP cells.
Multifunctional cells in the normal AP may tend to proliferate more than normal cells, and this behavior may play a role in AP cell plasticity. For example, during lactation, the rate of proliferation of PRL-producing cells increases dramatically (25). It is well known that, in addition to promoting hormone secretion, HRHs stimulate the mitotic activity of their target cells. Thus, for example, excessive GHRH secretion or GHRH overexpression results in dysregulated somatotrope proliferation, leading to hyperplasia and neoplastic transformation (26, 27). Multiresponsive cells are the target of multiple signals for proliferation; therefore, they should proliferate more than normal AP cells. If pituitary adenomas arose from multifunctional cells, then physiological or pathophysiological situations that promote transdifferentiation should favor tumor generation. Hypothyroidism, which induces transdifferentiation of somatotropes into thyrotropes, favors the appearance of pituitary adenomas (28) and estrogens, which promote transdifferentiation of somatotropes into mammotropes that also favor AP tumor generation (29). In addition, mutations of transcription factors involved in pituitary development and cell lineage commitment may also lead to pituitary adenomas (30). Thus, a link between pituitary plasticity and tumorigenesis deserves consideration.
A final point worthy of consideration is the possible therapeutic implications of our results. Because we find that pituitary adenoma cells contain large populations of cells responsive to both TRH and CRH, antagonists of HRH receptors, especially for the TRH and CRH receptors, should be considered to inhibit or delay AP tumor growth.
